Literature DB >> 14521618

Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients.

M Spreafico, F Peyvandi, D Pizzotti, M Moia, P M Mannucci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14521618     DOI： 10.1046/j.1538-7836.2003.00442.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  4 in total

1.  Extreme sensitivity to acenocoumarol therapy in patient with both VKORC.-1639 A/A and CYP2C9*1/*3 genotypes.

Authors:  Mirjana K Kovac; Ljiljana B Rakicevic; Dragica P Radojkovic
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

Review 2.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis.

Authors:  Jonatan D Lindh; Lennart Holm; Marine L Andersson; Anders Rane
Journal:  Eur J Clin Pharmacol       Date:  2008-11-25       Impact factor: 2.953

Review 4.  Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.

Authors:  Andrea L Jorgensen; Richard J FitzGerald; James Oyee; Munir Pirmohamed; Paula R Williamson
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.